Literature DB >> 18417989

Pyridoxine-related metabolite concentrations in normal and Down syndrome amniotic fluid.

Paddy Jim Baggot1, Anna Jane Y Eliseo, Nathaniel G DeNicola, Jeremy A Kalamarides, James D Shoemaker.   

Abstract

INTRODUCTION: Some studies of children with Down syndrome have found mild abnormalities in the metabolism of pyridoxine (vitamin B(6)); therefore the present question is whether such abnormalities might also be present in the amniotic fluid of fetuses with Down syndrome.
MATERIALS AND METHODS: Archived specimens of amniotic fluid were obtained from chromosomally normal and from fetuses with Down syndrome. Gas chromatography/mass spectrometry quantitized B-related metabolites, including oxalate, xanthurenate, kynurenine and 4-pyridoxic acid.
RESULTS: Oxalate, a marker of pyridoxine deficiency, was elevated in the amniotic fluid of fetuses with Down syndrome. This result was statistically significant. The other marker results were not statistically significant.
CONCLUSION: A marker of pyridoxine deficiency, oxalate is elevated in the amniotic fluid of fetuses with Down syndrome. These results in amniotic fluid are consistent with previous studies done in the urine of young children. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417989      PMCID: PMC2790743          DOI: 10.1159/000123610

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  10 in total

1.  Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease.

Authors:  J D Shoemaker; W H Elliott
Journal:  J Chromatogr       Date:  1991-01-02

Review 2.  Role of pyridoxine in oxalate metabolism.

Authors:  R Nath; S K Thind; M S Murthy; S Farooqui; R Gupta; H K Koul
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Infantile spasms associated with 5-hydroxytryptophan administration in patients with Down's syndrome.

Authors:  M Coleman
Journal:  Neurology       Date:  1971-09       Impact factor: 9.910

4.  Leukocyte pyridoxal phosphate and alkaline phosphatase in Down's syndrome and other retardates.

Authors:  S P Coburn; M Seidenberg
Journal:  Am J Clin Nutr       Date:  1969-09       Impact factor: 7.045

5.  The metabolism of vitamin B6 in Down's syndrome.

Authors:  E E McCoy; C Colombini; M Ebadi
Journal:  Ann N Y Acad Sci       Date:  1969-09-30       Impact factor: 5.691

6.  Intake of vitamins B6 and C and the risk of kidney stones in women.

Authors:  G C Curhan; W C Willett; F E Speizer; M J Stampfer
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

7.  Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones.

Authors:  S N Gershoff; E L Prien
Journal:  Am J Clin Nutr       Date:  1967-05       Impact factor: 7.045

8.  5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome.

Authors:  S M Pueschel; R B Reed; C E Cronk; B I Goldstein
Journal:  Am J Dis Child       Date:  1980-09

9.  A double blind study of vitamin B6 in Down's syndrome infants. Part 2--Cortical auditory evoked potentials.

Authors:  J Frager; A Barnet; I Weiss; M Coleman
Journal:  J Ment Defic Res       Date:  1985-09

10.  A double blind study of vitamin B6 in Down's syndrome infants. Part 1--Clinical and biochemical results.

Authors:  M Coleman; S Sobel; H N Bhagavan; D Coursin; A Marquardt; M Guay; C Hunt
Journal:  J Ment Defic Res       Date:  1985-09
  10 in total
  1 in total

1.  One-step metabolomics: carbohydrates, organic and amino acids quantified in a single procedure.

Authors:  James D Shoemaker
Journal:  J Vis Exp       Date:  2010-06-25       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.